| Literature DB >> 25455877 |
Sandip Basu1, Rakesh Kumar2, Rohit Ranade3.
Abstract
This article reviews the major treatment response evaluation guidelines in the domain of cancer imaging and how the potential of PET imaging, particularly with fluorodeoxyglucose, is increasingly explored in this important aspect of cancer management. Certain disease-specific response criteria (such as in lymphoma) are also reviewed with emphasis on the changes made over time and the main areas of concern in PET interpretation. The major present clinical applications are illustrated and potential new areas are discussed with regard to clinical applications in the future. Finally, the evolving role of newer and novel PET metrics, which hold promise in treatment response evaluation, is illustrated with examples.Entities:
Keywords: EORTC 1999; Global metabolic burden; Metabolic tumor volume; PERCIST; RECIST1.0; Revised RECIST guideline (version 1.1); WHO criteria; Whole-body metabolic burden
Mesh:
Substances:
Year: 2014 PMID: 25455877 DOI: 10.1016/j.cpet.2014.09.002
Source DB: PubMed Journal: PET Clin ISSN: 1556-8598